title: Isotretinoin in severe, recalcitrant cystic acne: a review.
abstract: Isotretinoin, an isomer of retinoic acid, recently has been approved by the Food and Drug Administration for treatment of severe, recalcitrant acne. The most impressive effects include inhibition of sebum production and a reversible decrease in sebaceous gland size. Isotretinoin has proved to be an effective drug; response to therapy has been seen in virtually 100 percent of patients treated. Almost all patients experience reversible cutaneous and mucous-membrane symptoms while on isotretinoin treatment. Other common side effects include conjunctivitis (38 percent) and eye irritation (50 percent). The recommended dosage is 1-2 mg/kg/d for no longer than 16 weeks. Isotretinoin is currently the treatment of choice for severe, recalcitrant acne; however, because of potential side effects associated with retinoids, isotretinoin should be reserved for those patients who are unresponsive to conventional therapy, including topical and systemic antibiotics.
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005123:Eye / Q000187:drug effects; D006801:Humans; D007408:Intestinal Absorption; D015474:Isotretinoin; D012629:Sebum / Q000187:drug effects; D014018:Tissue Distribution; D014212:Tretinoin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D014280:Triglycerides; D014212:Tretinoin; D015474:Isotretinoin